Skip to content
Open·Ingested 255 days ago, not re-verified since. Deadlines can change; confirm on the official page.

Blueprint Neurotherapeutics Network (BPN): Biologic-based Drug Discovery and Development for Disorders of the Nervous System (UG3/UH3 Clinical Trial Optional)

National Institutes of Health

Apply at National Institutes of Health

Free. Verify your email, then we send one reminder only.

Posted
Dec 17, 2025
Closes
Aug 18, 2027 (in 353 days)

Get alerted when new grant funding like this opens.

Checking your account…

Free. Everyone sees new listings after 10 days. Unsubscribe anytime.

Classification and identifiers

Solicitation number
PAR-24-293
Assistance listing (CFDA)
93.121

Amount

Amount not published by the funder

Who can apply

Private universitiesTribal organizationsState governmentsNonprofits (non-501c3)Special districtsPublic universities

Private colleges and universities, State government agencies, and Public colleges and universities can all apply here. Check the eligibility details below to see if your organization fits.

Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

About this opportunity

The Blueprint Neurotherapeutics Network for Biologics (BPN-Biologics) provides support for biologic-based therapeutic discovery and development, from lead optimization through phase I clinical testing. This Funding Opportunity Announcement (FOA) supports preclinical discovery and development of potential therapeutic Biotechnology Products and Biologics including, but not limited to, large biologic macromolecules, (e.g., proteins, antibodies, and peptides), gene-based therapies (i.e., oligonucleotide- and viral-based), cell therapies, and novel emerging therapies (e.g., microbial and microbiome therapies). Applicants will collaborate with NIH-funded consultants and can augment their project with NIH contract research organizations (CROs) that specialize in manufacturing, scaling, pharmacoki...

Refine this search